Marinus Pharmaceuticals logo

Marinus PharmaceuticalsNASDAQ: MRNS

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

31 July 2014

Next earnings report:

05 March 2025

Last dividends:

N/A

Next dividends:

N/A
$17.92 M
-97%vs. 3y high
23%vs. sector
-vs. 3y high
-vs. sector
-100%vs. 3y high
13%vs. sector
-98%vs. 3y high
15%vs. sector

Price

after hours | 24 min ago
$0.32+$0.01(+2.33%)

Dividend

No data over the past 3 years
$8.54 M$10.51 M
$8.54 M-$24.23 M

Analysts recommendations

Institutional Ownership

MRNS Latest News

Marinus Pharmaceuticals (MRNS) Reports Q3 Loss, Misses Revenue Estimates
zacks.com12 November 2024 Sentiment: NEUTRAL

Marinus Pharmaceuticals (MRNS) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of $0.44. This compares to loss of $0.61 per share a year ago.

Marinus Pharmaceuticals to Highlight Clinical Progress and Commercial Launch Preparedness for ZTALMY® in TSC at Investor and Analyst Day
businesswire.com20 September 2024 Sentiment: POSITIVE

RADNOR, Pa.--(BUSINESS WIRE)--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today is hosting an Investor and Analyst Day and will present an in-depth review of the Company's development program for ZTALMY® (ganaxolone) oral suspension CV in tuberous sclerosis complex (TSC) ahead of the Phase 3 TrustTSC trial topline data readout anticipated in the first half of the fourth quarter of 2024.

Marinus Pharmaceuticals to Host Investor and Analyst Day on Friday, September 20, 2024
businesswire.com19 August 2024 Sentiment: POSITIVE

RADNOR, Pa.--(BUSINESS WIRE)--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, will host an Investor and Analyst Day on Friday, September 20 from 9:00 a.m. to 12:00 p.m. Eastern Time in New York and via webcast. The event will feature presentations from Marinus management and key opinion leaders with a focus on the Company's development program for ZTALMY® (ganaxolone) oral suspension CV in.

Marinus Pharmaceuticals, Inc. (MRNS) Q2 2024 Earnings Call Transcript
seekingalpha.com13 August 2024 Sentiment: POSITIVE

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS ) Q2 2024 Earnings Conference Call August 13, 2024 8:30 AM ET Company Participants Sonya Weigle - Chief People and Investor Relations Officer Scott Braunstein - Chairman and Chief Executive Officer Lisa Lejuwaan - Senior Vice President and Business Unit Lead, Rare Genetic Epilepsy Joseph Hulihan - Chief Medical Officer Steven Pfanstiel - Chief Financial Officer and Chief Operating Officer Conference Call Participants Charles Duncan - Cantor Fitzgerald Joseph Thome - TD Cowen Andrew Tsai - Jefferies Douglas Tsao - H.C. Wainwright Marc Goodman - Leerink Operator Greetings and welcome to Marinus Pharmaceuticals' Second Quarter Financial Results and Business Update Call.

Marinus Pharmaceuticals (MRNS) Reports Q2 Loss, Misses Revenue Estimates
zacks.com13 August 2024 Sentiment: NEGATIVE

Marinus Pharmaceuticals (MRNS) came out with a quarterly loss of $0.60 per share versus the Zacks Consensus Estimate of a loss of $0.59. This compares to loss of $0.61 per share a year ago.

Investors Are Invited To Participate In The Marinus Pharmaceuticals Inc Fraud Investigation With The Schall Law Firm
accesswire.com07 August 2024 Sentiment: NEGATIVE

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Marinus Pharmaceuticals, Inc. ("Marinus" or "the Company") (NASDAQ:MRNS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

MRNS Investors Have Opportunity To Join Marinus Pharmaceuticals Inc Fraud Investigation With The Schall Law Firm
accesswire.com06 August 2024 Sentiment: NEGATIVE

LOS ANGELES, CA / ACCESSWIRE / August 6, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Marinus Pharmaceuticals, Inc. ("Marinus" or "the Company") (NASDAQ:MRNS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Levi & Korsinsky Notifies Marinus Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - MRNS
accesswire.com05 August 2024 Sentiment: NEGATIVE

NEW YORK, NY / ACCESSWIRE / August 5, 2024 / If you suffered a loss on your Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/marinus-pharmaceuticals-inc-lawsuit-submission-form?prid=93921&wire=1 or contact Joseph E. Levi, Esq.

Marinus Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before August 5, 2024 to Discuss Your Rights - MRNS
accesswire.com05 August 2024 Sentiment: NEGATIVE

NEW YORK, NY / ACCESSWIRE / August 5, 2024 / If you suffered a loss on your Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/marinus-pharmaceuticals-inc-lawsuit-submission-form?prid=93901&wire=1 or contact Joseph E. Levi, Esq.

Marinus Pharmaceuticals, Inc. Class Action: The Gross Law Firm Reminds Marinus Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of August 5, 2024 - MRNS
prnewswire.com05 August 2024 Sentiment: NEGATIVE

NEW YORK , Aug. 5, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS). Shareholders who purchased shares of MRNS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.

What type of business is Marinus Pharmaceuticals?

Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ZTALMY product candidate acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential. It is developing ganaxolone for treating genetic epilepsy disorders, such as PCDH19-related epilepsy, and tuberous sclerosis complex. Marinus Pharmaceuticals, Inc. has license agreement with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc.; and collaboration agreement with Orion Corporation and Tenacia Biotechnology (Shanghai) Co., Ltd. Marinus Pharmaceuticals, Inc. was incorporated in 2003 and is headquartered in Radnor, Pennsylvania.

What sector is Marinus Pharmaceuticals in?

Marinus Pharmaceuticals is in the Healthcare sector

What industry is Marinus Pharmaceuticals in?

Marinus Pharmaceuticals is in the Biotechnology industry

What country is Marinus Pharmaceuticals from?

Marinus Pharmaceuticals is headquartered in United States

When did Marinus Pharmaceuticals go public?

Marinus Pharmaceuticals initial public offering (IPO) was on 31 July 2014

What is Marinus Pharmaceuticals website?

https://marinuspharma.com

Is Marinus Pharmaceuticals in the S&P 500?

No, Marinus Pharmaceuticals is not included in the S&P 500 index

Is Marinus Pharmaceuticals in the NASDAQ 100?

No, Marinus Pharmaceuticals is not included in the NASDAQ 100 index

Is Marinus Pharmaceuticals in the Dow Jones?

No, Marinus Pharmaceuticals is not included in the Dow Jones index

When was Marinus Pharmaceuticals the previous earnings report?

No data

When does Marinus Pharmaceuticals earnings report?

The next expected earnings date for Marinus Pharmaceuticals is 05 March 2025